1
|
Boutros J, Martin N, Otto J, Marquette CH, Lhomel B, Naghavi AO, Schiappa R, Bondiau PY, Doyen J. Combining Stereotactic Radiotherapy and Conventional Radiotherapy for Peripheral Locally Advanced Lung Cancer. Clin Oncol (R Coll Radiol) 2023; 35:624-625. [PMID: 37330363 DOI: 10.1016/j.clon.2023.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 06/02/2023] [Indexed: 06/19/2023]
Affiliation(s)
- J Boutros
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France; Department of Pulmonary Medicine and Oncology, Centre Hospitalier Universitaire de Nice, Nice, France.
| | - N Martin
- Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France
| | - J Otto
- Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France
| | - C-H Marquette
- Department of Pulmonary Medicine and Oncology, Centre Hospitalier Universitaire de Nice, Nice, France; University of Côte D'Azur, Nice, France
| | - B Lhomel
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France; University of Côte D'Azur, Nice, France
| | - A O Naghavi
- Department of Radiation Oncology and Research Institute, Tampa, FL, USA
| | - R Schiappa
- Department of Biostatistics, Centre Antoine-Lacassagne, Nice, France
| | - P-Y Bondiau
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France; University of Côte D'Azur, Nice, France
| | - J Doyen
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France; University of Côte D'Azur, Nice, France
| |
Collapse
|
2
|
Zalcman G, Madroszyk Flandin AC, Molinier O, Dayen C, Egenod T, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Langlais A, Morin F, Antoine M, Westeel V, Toffart A. 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. ESMO Open 2022; 7:100418. [PMID: 35227966 PMCID: PMC9058895 DOI: 10.1016/j.esmoop.2022.100418] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 01/10/2022] [Accepted: 02/02/2022] [Indexed: 12/25/2022] Open
Abstract
Introduction ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and real-world data are lacking. We investigate the efficacy and safety of lorlatinib, a third-generation TKI targeting ALK and ROS1, in patients with ROS1+ NSCLC treated through an expanded access program. Methods Consecutive patients with advanced ROS1+ NSCLC treated with lorlatinib between October 2015 and June 2019 were included. Data were collected from medical records. The primary endpoint was progression-free survival. Results Out of the 80 patients included, 47(59%) were female, 49(62%) never smokers (less than 100 cigarettes over the lifetime), and 68(85%) had stage IV NSCLC at diagnosis. Most frequent histology was adenocarcinoma (95%) and median age was 58.2 years. At the time of lorlatinib initiation, 51(64%) patients had brain metastases and 55(81%) were PS 0-1. Lorlatinib was administered as second/third/fourth/fifth+ line in 29%/28%/18%/26% of patients. All patients previously received at least one ROS1 TKI, and 55(69%) previously received chemotherapy. Median follow-up from lorlatinib initiation was 22.2 months. Median progression-free survival and overall survival from lorlatinib initiation were 7.1 months [95% confidence interval (CI) 5.0-9.9 months] and 19.6 months (95% CI 12.3-27.5 months). Median duration of treatment with lorlatinib was 7.4 months (95% CI 6.5-13.1 months). Overall response and disease control rates were 45% and 82%, respectively. The central nervous system response rate was 72%. Treatment was stopped due to toxicity in 10 patients (13%). The safety profile was consistent with previously published data. Conclusions Lorlatinib is a major treatment option for advanced refractory ROS1+ NSCLC in treatment strategy. Data are lacking on lorlatinib efficacy in advanced refractory ROS1+ NSCLC. Lorlatinib median progression-free survival and objective response rate were 7.1 months and 45%, respectively. Lorlatinib represents a major treatment option for patients with a ROS1+ NSCLC.
Collapse
|
4
|
Thomas D, Lan N, Jones C, Raju V, Soon J, Otto J, Wood C, Spencer R, Rankin J, Dwivedi G, Ihdayhid A. Evaluation of a Chest Pain Evaluation Pathway in the Emergency Department Utilising Computed Tomography Coronary Angiography as a First-Line Outpatient Test. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
5
|
Huangfu G, Jaltotage B, Pang J, Lan N, Abraham A, Otto J, Ihdayhid A, Rankin J, Watts G, Ayonrinde O, Dwivedi G. CT Evaluation of Hepatic Fat: A Novel Marker for High-Risk Coronary Atherosclerosis in Familial Hypercholesterolaemia. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Girard N, Mazieres J, Otto J, Lena H, Lepage C, Egenod T, Smith D, Madelaine J, Gérinière L, El Hajbi F, Ferru A, Clément-Duchêne C, Madroszyk A, Desrame J, Morin F, Langlais A, Michel P, Louvet C, Westeel V, Walter T. LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
7
|
Verrill L, Boyer M, Williams L, Otto J, Lando A, Dawood N, Liggans G. Hand Washing Observations in Fast-Food and Full-Service Restaurants: Results from the 2014 U.S. Food and Drug Administration Retail Food Risk Factors Study. J Food Prot 2021; 84:1016-1022. [PMID: 33465242 DOI: 10.4315/jfp-20-412] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Accepted: 01/06/2021] [Indexed: 11/11/2022]
Abstract
ABSTRACT Properly executed hand washing by food service employees can greatly minimize the risk of transmitting foodborne pathogens to food and food contact surfaces in restaurants. However, food service employee hand washing is often not done correctly or does not occur as often as it should. The purpose of this study was to assess the relative impact of (i) the convenience and accessibility of hand washing facilities; (ii) the maintenance of hand washing supplies, (iii) multiunit status, (iv) having a certified food protection manager, and (v) having a food safety management system for compliance with proper hand washing. Results revealed marked differences in hand washing behaviors between fast-food and full-service restaurants; 45% of 425 fast-food restaurants and 57% of 396 full-service restaurants were out of compliance for washing hands correctly, and 57% of fast-food restaurants and 78% of full-service restaurants were out of compliance for employee hands being washed when required. Logistic regression results indicated the benefits of accessibility and maintenance of the hand washing sink and of a food safety management system for increasing the likelihood of employees washing hands when they are supposed to and washing them correctly when they do. HIGHLIGHTS
Collapse
Affiliation(s)
- L Verrill
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - M Boyer
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - L Williams
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - J Otto
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - A Lando
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - N Dawood
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| | - G Liggans
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Room 2C-095, College Park, Maryland 20740, USA
| |
Collapse
|
8
|
Baldacci S, Besse B, Avrillon V, Mennecier B, Dubray-Longeras P, Mazieres J, Descourt R, Duruisseaux M, Quantin X, Doubre H, Monnet I, Moro-Sibilot D, Schneider S, Cousin S, Merle P, Otto J, Langlais A, Morin F, Westeel V, Girard N. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1617] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet P, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier-Ait Oukhatar C, Blay J. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol 2020; 31:289-294. [DOI: 10.1016/j.annonc.2019.10.022] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 10/08/2019] [Accepted: 10/20/2019] [Indexed: 12/21/2022] Open
|
10
|
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 2019; 30:1985-1991. [PMID: 31584608 DOI: 10.1093/annonc/mdz407] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed approvals. Efficacy and safety was then assessed using a two-stage Simon phase II trial design. When the study design was designed, crizotinib was approved only as monotherapy for adults with anaplastic lymphoma kinase plus non-small-cell lung cancers (NSCLC). PATIENTS AND METHODS Advanced NSCLC patients with c-MET ≥6 copies, c-MET-mutated, or ROS-1-translocated tumours were enrolled in one of the three cohorts. Patients were treated with crizotinib 250 mg twice daily. Efficacy was assessed using the objective response rate (ORR) after two cycles of crizotinib as primary outcome. Secondary outcomes included disease control rate at four cycles, best ORR, progression-free survival, overall survival, and drug tolerance. RESULTS From August 2013 to March 2018, 5606 patients had their tumour tested for crizotinib targeted molecular alterations: 252 patients had c-MET ≥6 copies, 74 c-MET-mutation, and 78 ROS-1-translocated tumour. Finally, 25 patients in the c-MET ≥6 copies cohort, 28 in the c-MET-mutation cohort, and 37 in the ROS-1-translocation cohort were treated in the phase II trial. The ORR was 16% in the c-MET ≥6 copies cohort, 10.7% in the mutated, and 47.2% in the ROS-1 cohort. The best ORR during treatment was 32% in the c-MET-≥6 copies cohort, 36% in the c-MET-mutated, and 69.4% in the ROS-1-translocation cohort. Safety data were consistent with that previously reported. CONCLUSIONS Crizotinib activity in patients with ROS1-translocated tumours was confirmed. In the c-MET-mutation and c-MET ≥6 copies cohorts, despite insufficient ORR after two cycles of crizotinib, there are signs of late response not sufficient to justify the development of crizotinib in this indication. The continued targeting of c-MET with innovative therapies appears justified. CLINICAL TRIAL NUMBER NCT02034981.
Collapse
Affiliation(s)
- D Moro-Sibilot
- Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble; Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris.
| | - N Cozic
- Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, INSERM U1018, ESP, Paris-Saclay and Paris-Sud Universities, Villejuif
| | - M Pérol
- Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon
| | - J Mazières
- Pneumology Department, Toulouse University Hospital and Paul Sabatier University, Toulouse
| | - J Otto
- Department of Medicine, Antoine Lacassagne Cancer Centre, Nice
| | - P J Souquet
- Department of Pneumology and Thoracic Oncology, Lyon Sud Hospital Center, Hospices Civils de Lyon, Pierre Bénite
| | - R Bahleda
- Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif
| | - M Wislez
- Pneumology Department, Tenon Hospital, AP-HP and "Pierre and Marie Curie" University, Paris
| | - G Zalcman
- Thoracic Oncology Department-CIC INSERM 1425, Bichat University Hospital, AP-HP, Paris; Paris-Diderot University, Paris
| | | | - F Barlési
- Multidisciplinary Oncology & Therapeutic Innovations Department, APHM and Aix Marseille University, INSERM, CNRS, CRCM, Marseille
| | - B Mennecier
- Pneumology Department, Strasbourg University Hospital, Strasbourg
| | - I Monnet
- Pneumology Department, CHIC Creteil, Créteil
| | - R Sabatier
- Department of Medical Oncology, Inserm 1068, CNRS UMR7258, CRCM, Paoli-Calmettes Institute and Aix-Marseille University, Marseille
| | - S Bota
- Pneumology Department, Charles Nicolle Hospital, Rouen University Hospital, Rouen
| | - C Dubos
- Pneumology Department, François Baclesse Cancer Centre, Caen
| | - V Verriele
- Anatomy and Pathological Cytologies Department, Paul Papin Cancer Centre, ICO, Angers
| | - V Haddad
- Department of Tumour Biology, Léon Bérard Cancer Centre, Lyon
| | - G Ferretti
- Radiology and Medical Imaging Department, Grenoble-Alpes University Hospital, Grenoble
| | - A Cortot
- Department of Thoracic Oncology, Lille University Hospital and University of Lille, Lille
| | - F De Fraipont
- Molecular Genetic Unit: Hereditary Diseases and Oncology, Grenoble-Alpes University Hospital, Grenoble
| | - M Jimenez
- Research and Development UNICANCER, Paris
| | | | - G Vassal
- Clinical Research Division, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
11
|
Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, Borchiellini D, Benisvy D, Ouvrier MJ, Zwarthoed C, Schiazza A, Ilie M, Ghalloussi H, Koulibaly PM, Darcourt J, Otto J. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging 2019; 47:1158-1167. [PMID: 31760467 DOI: 10.1007/s00259-019-04573-4] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 10/10/2019] [Indexed: 12/11/2022]
Abstract
PURPOSE This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome. DESIGN Fifty patients with metastatic NSCLC were included before pembrolizumab or nivolumab initiation. FDG-PET scan was performed at baseline and after 7 weeks of treatment (PETinterim1) and different criteria/parameters of tumor response were assessed, including PET response criteria in solid tumors (PERCIST). If a first PERCIST progressive disease (PD) without clinical worsening was observed, treatment was continued and a subsequent FDG-PET (PETinterim2) was performed at 3 months of treatment. Pseudo-progression (PsPD) was defined as a PERCIST response/stability on PETinterim2 after an initial PD. If a second PERCIST PD was assessed on PETinterim2, a homogeneous progression of lesions (termed immune homogeneous progressive-disease: iPDhomogeneous) was distinguished from a heterogeneous evolution (termed immune dissociated-response: iDR). A durable clinical benefit (DCB) of immunotherapy was defined as treatment continuation over a 6-month period. The association between PET evolutive profiles and DCB was assessed. RESULTS Using PERCIST on PETinterim1, 42% (21/50) of patients showed a response or stable disease, most of them (18/21) reached a DCB. In contrast, 58% (29/50) showed a PD, but more than one-third (11/29) were misclassified as they finally reached a DCB. No standard PETinterim1 criteria could accurately distinguished responding from non-responding patients. Treatment was continued in 19/29 of patients with a first PERCIST PD; the subsequent PETinterim2 demonstrated iPDhomogeneous, iDR and PsPD in 42% (8/19), 26% (5/19), and 32% (6/19), respectively. Whereas no patients with iPDhomogeneous experienced a DCB, all patients with iDR and PsPD reached a clinical benefit to immunotherapy. CONCLUSION In patients with a first PD on PERCIST and treatment continuation, a subsequent PET identifies more than half of them with iDR and PsPD, both patterns being strongly associated with a clinical benefit of immunotherapy.
Collapse
Affiliation(s)
- O Humbert
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France. .,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France.
| | - N Cadour
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M Paquet
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - R Schiappa
- Department of Biostatistics, Centre Antoine-Lacassagne, UCA, Nice, France
| | - M Poudenx
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - D Chardin
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France.,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France
| | - D Borchiellini
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France.,Clinical Research and Innovation Office, Centre Antoine-Lacassagne, UCA, Nice, France
| | - D Benisvy
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M J Ouvrier
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - C Zwarthoed
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - A Schiazza
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M Ilie
- Laboratory of Clinical and Experimental Pathology, Hospital-Integrated Biobank (BB-0033-00025), Nice Hospital University, FHU OncoAge, UCA, Nice, France
| | - H Ghalloussi
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - P M Koulibaly
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - J Darcourt
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France.,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France
| | - J Otto
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| |
Collapse
|
12
|
Guo L, Montaudié H, Bouhlel L, Picard A, Otto J, Falk A, Poudenx M, Bondiau PY, Gal J, Lacour JP, Passeron T, Sumodhee S, Doyen J. Impact du schéma d’irradiation sur la survie des patients atteints de carcinomes bronchiques non à petites cellules et de mélanomes évolués traités par l’association d’irradiation et d’inhibiteurs de checkpoint de l’immunité. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Abstract
Chronic neuropathic pain has a prevalence of 6.9-10% in the general population. The current recommendations for treatment are presented based on a literature search. Neuropathic pain requires the use of co-analgesic, antidepressant, anticonvulsant drugs and topical agents because non-opioid analgesic drugs are usually ineffective. The use of meta-analyses tricyclic antidepressants, selective serotonin-norephinephrine reuptake inhibitors, and calcium channel anticonvulsants are recommended as the drugs of first choice. Under certain conditions chronic neuropathic pain can be treated with opioids. Topical therapeutics are only used to treat peripheral neuropathic pain. At present the use of drugs is independent of the etiology of the pain. Comorbidities, concomitant medication, potential side effects and patients' age have to be considered in treatment planning.
Collapse
Affiliation(s)
- J Otto
- Sektion für Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
| | - J Forstenpointner
- Sektion für Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
| | - A Binder
- Klinik für Neurologie, Klinikum Saarbrücken gGmbH, Saarbrücken, Deutschland
| | - R Baron
- Sektion für Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland.
| |
Collapse
|
14
|
Cortot AB, Madroszyk A, Giroux Leprieur E, Molinier O, Quoix EA, Berard H, Otto J, Rault I, Raimbourg J, Hureaux J, Moreau L, Debieuvre D, Morel H, Denis MG, Amour E, Morin F, Moro-Sibilot D, Cadranel J. Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.9079] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9079 Background: First-line treatment of metastatic EGFR-mutated NSCLC relies on EGFR-TKIs. However, all patients (pts) eventually develop progression. Dual inhibition of EGFR with afatinib (A), an irreversible pan-erbB TKI, and cetuximab (C), an EGFR monoclonal antibody, has shown activity in EGFR-mutated pts with acquired resistance to TKIs, regardless of the T790M status. Methods: We conducted a phase II randomized trial in advanced NSCLC pts harboring an activating EGFR mutation, who had not received prior therapy. Pts were treated with A (40 mg/d) until progression alone or with C 500 mg/m² every 2 weeks during 6 months (mos) (beginning at D15 at 250 mg/m²). Primary endpoint was time-to-treatment failure (TTF) at 9 mos for pts with del19 and L858R mutations. Secondary endpoints include safety, progression-free survival (PFS), overall survival (OS). Prospective monitoring of the T790M mutation was performed on circulating tumoral DNA (ctDNA) by digital PCR. Results: Trial was stopped early due to futility analysis after 118 pts were enrolled (59 in each arm). Baseline characteristics were balanced between the 2 arms, and especially for the types of EGFR mutation (del19, 55.9 vs 50.8%; L858R, 39 vs 40.7%; others, 5.1 vs 8.5% in AC and A arms, respectively). Treatment-related AEs of any grades were similar, although there was an excess of grade 3 AEs in the AC arm (50 vs 37.3%), but no of grade 5. The excess in grade 3-5 AEs was essentially due to cutaneous (96.6 vs 81.4%), eyes (32.8 vs 27.1%), hematological (22.4 vs 15.3%) but not to digestive toxicities (89.7 vs 98.3%). Among the 117 pts included in the efficacy analysis, 9-months TTF was 63.3% (47.5-75.6) in arm A and 65.8% (50.1-77.66) in arm AC. Median TTF was 11.1 mos (8.3-not reached [NR]) and 10.8 mos (9.2-13.7) in arms A and AC, respectively. Median PFS was 11.1 mos (8.3-NR) and 12.8 mos (9.2-13.7), respectively. Median OS was 20.8 mos (17.5-NR) and NR (17-NR), respectively. Conclusions: Efficacy of AC was similar to that of A alone. These results don’t support further evaluation of this combination in this setting. Results of ctDNA monitoring will be reported during the meeting. Clinical trial information: NCT02716311.
Collapse
Affiliation(s)
| | | | | | | | | | - Henri Berard
- Hopital D'instruction Des Armes Sainte-Anne, Toulon, France
| | | | | | | | | | - Lionel Moreau
- Centre Hospitalier Pneumologie Colmar, Colmar, France
| | | | | | | | | | - Franck Morin
- Intergroupe Francophone de Cancérologie Thoracique, Paris, France
| | | | - Jacques Cadranel
- Hôpital Tenon, AP-HP and Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France
| | | |
Collapse
|
15
|
Pujol J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Thiberville L, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault P, Mazieres J, Antoine M, Langlais A, Morin F, Souquet P. Étude de phase II randomisée non comparative de l’anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d’un cancer du poumon à petites cellules (CBPC) : résultats de l’essai IFCT-1603. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Milano G, Refae S, Gal J, Ebran N, Otto J, Shell S, Everts R, Chamorey E, Saada-Bouzid E. A SNP germinal signature for predicting checkpoint inhibitor treatment outcome. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Mazieres J, Montané L, Barlesi F, Coudert B, Souquet P, Otto J, Gervais R, Moro-Sibilot D, Monnet I, Brain E, Huillard O, Quéré G, Debieuvre D, Fabre E, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier - Ait Oukhatar C, Blay J. OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.302] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Quoix E, Audigier Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Dumont P, Moreau L, Madelaine J, Margery J, Debieuvre D, Renault P, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ. Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Pujol JL, Greillier L, Audigier Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Thiberville L, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault P, Mazieres J, Antoine M, Langlais A, Morin F, Souquet PJ. A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy298] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Nudehi S, Larson C, Prusinski W, Kotfer D, Otto J, Beyers E, Schoer J, Palumbo R. Solar thermal decoupled water electrolysis process II: An extended investigation of the anodic electrochemical reaction. Chem Eng Sci 2018. [DOI: 10.1016/j.ces.2017.12.032] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Brüggemann P, Otto J, Lorenz N, Schorsch S, Szczepek AJ, Böcking B, Mazurek B. Erratum to: Long-term changes in multimodal intensive tinnitus therapy. A 5-year follow-up. HNO 2018; 66:211. [PMID: 29426995 DOI: 10.1007/s00106-018-0484-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Erratum to:HNO 2018 66 (Suppl):S34-S38 https://doi.org/10.1007/s00106-017-0463-4 Figure 1 was published incorrectly in the online version of this paper. The correct Figure is reproduced below.
Collapse
Affiliation(s)
- P Brüggemann
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - J Otto
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - N Lorenz
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - S Schorsch
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - A J Szczepek
- Department of Otorhinolaryngology, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - B Böcking
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - B Mazurek
- Tinnituszentrum, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
22
|
Koehler U, Hildebrandt O, Krönig J, Grimm W, Otto J, Hildebrandt W, Kinscherf R. [Chronic hypoxia and cardiovascular risk : Clinical significance of different forms of hypoxia]. Herz 2017; 43:291-297. [PMID: 28474128 DOI: 10.1007/s00059-017-4570-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 03/13/2017] [Accepted: 04/04/2017] [Indexed: 12/19/2022]
Abstract
It is of fundamental importance to differentiate whether chronic hypoxia occurs intermittently or persistently. While chronic intermittent hypoxia (CIH) is found typically in patients with obstructive sleep apnea (OAS), chronic persistent hypoxia (CPH) is typically diagnosed in patients with chronic lung disease. Cardiovascular risk is markedly increased in patients with CIH compared to patients with CPH. The frequent change between oxygen desaturation and reoxygenation in patients with CIH is associated with increased hypoxic stress, increased systemic inflammation, and enhanced adrenergic activation followed by endothelial dysfunction and increased arteriosclerosis. The pathophysiologic consequences of CPH are less well understood. The relationship between CPH and the development of pulmonary hypertension, pulmonary heart disease as well as polycythemia has been established.
Collapse
Affiliation(s)
- U Koehler
- Klinik für Innere Medizin, SP Pneumologie, Intensiv- und Schlafmedizin, Philipps-Universität, Baldingerstraße 1, 35043, Marburg, Deutschland.
| | - O Hildebrandt
- Klinik für Innere Medizin, SP Pneumologie, Intensiv- und Schlafmedizin, Philipps-Universität, Baldingerstraße 1, 35043, Marburg, Deutschland
| | - J Krönig
- Klinik für Innere Medizin, SP Pneumologie, Intensiv- und Schlafmedizin, Philipps-Universität, Baldingerstraße 1, 35043, Marburg, Deutschland
| | - W Grimm
- Klinik für Innere Medizin, SP Kardiologie, Intensivmedizin und Angiologie, Philipps-Universität, Marburg, Deutschland
| | - J Otto
- Medizinische Zellbiologie, Institut für Anatomie und Zellbiologie, Philipps-Universität, Marburg, Deutschland
| | - W Hildebrandt
- Medizinische Zellbiologie, Institut für Anatomie und Zellbiologie, Philipps-Universität, Marburg, Deutschland
| | - R Kinscherf
- Medizinische Zellbiologie, Institut für Anatomie und Zellbiologie, Philipps-Universität, Marburg, Deutschland
| |
Collapse
|
23
|
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D. Efficacité du bévacizumab associé à un doublet de chimiothérapie à base de sels de platine en première ligne de traitement des cancers du poumon ALK-réarrangés : analyse des données de l’étude IFCT-1302 CLINALK. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Doyen J, Leysalle A, Gal J, Poudenx M, Otto J, Guerder C, Padovani B, Venissac N, Bondiau P. Chimioradiothérapie concomitante suivie d’une irradiation stéréotaxique des cancers bronchiques non à petite cellules : résultats finaux de l’essai de phase 1 Cybertaxcis. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.07.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Falk A, Ilié M, Long E, Tanga V, Lespinet V, Bordone O, Allegra M, Ribeyre C, Otto J, Poudenx M, Marquette CH, Hofman V, Hofman P. Liquid biopsy testing in routine clinical management of advanced non-small cell lung cancer: clinical validation in a single biopathology laboratory. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Otto J, Schaudinn A, Linder N, Ganzer R, Stolzenburg J, Horn L, Garnov N, Kahn T, Moche M, Busse H. MR-gesteuerte Interventionen an der Prostata. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Otto J, Reiss-Zimmermann M, Thörmer G, Schaudinn A, Garnov N, Stolzenburg J, Horn L, Moche M, Kahn T, Busse H. Prospektiver Vergleich von Bildqualität und Tumordetektion anhand der 3-T Prostata-MRT mit und ohne Verwendung einer Endorektalspule. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin J, Marquette C, Hofman V, Hofman P. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27:147-53. [DOI: 10.1093/annonc/mdv489] [Citation(s) in RCA: 383] [Impact Index Per Article: 47.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 10/06/2015] [Indexed: 12/23/2022] Open
|
29
|
Thron A, Krings T, Otto J, Mull M, Schroeder JM. The Transdural Course of Radicular Spinal Cord Veins--A Microangiographical and Microscopical Study. Clin Neuroradiol 2015; 25:361-9. [PMID: 26510557 DOI: 10.1007/s00062-015-0476-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Accepted: 10/01/2015] [Indexed: 11/30/2022]
Abstract
PURPOSE This study focuses on the following questions: What are the morphological features at the transdural course of radiculomedullary veins? How are these short transdural segments that may harbour pathological arteriovenous shunts connected to the internal vertebral venous plexus? Is the conception of a reflux-impeding mechanism at the transdural segment indispensable and convincing? METHODS A total of 102 radiculospinal veins were studied microscopically at various levels of the spinal canal using serial paraffin and semi-thin sections. In addition, 26 vessels were investigated microangiographically following orthograde (12) or attempted retrograde (14) opacification of the intradural venous segment with barium sulphate. After paraplast-embedding, contact-microradiographs were taken using high-resolution spectroscopic plates. RESULTS At their transdural course, the veins showed narrowing of their lumen accompanied by changes in the vessel wall composition and a tortuous course. Two structurally distinct arrangements of the transdural segment could be identified: A slit type was seen in 60% of the veins studied and a bulge- or nodular type was seen in 35% of the veins. In total, 5% of cases could not be assigned to either one of these types. Reflux to radicular veins from the outside of the dura mater could be produced in 2 out of 14 specimens. The extradural venous plexus, which primarily receives the radicular vein, was composed more frequently of lacunar spaces rather than plexiform blood vessel convolutions. Rare observations were fibrotic, blind ending radiculomedullary veins and continuation of a distinct venous blood vessel after crossing the dura. CONCLUSIONS Reflux from the epidural plexus to radicular veins is not reliably stopped at the dural level and possibly physiological. Different arrangements of the transdural course of the veins appear to be at least appropriate to modulate flow. The purpose for two different types of radicular vein exit is unclear. The clinical impact of disturbed reflux-control is uncertain, which is in stark contrast to the severe consequences resulting from dural arteriovenous shunts. The functional role of the probably predominant epidural venous plexus for the spinal cord blood circulation remains poorly understood.
Collapse
Affiliation(s)
- A Thron
- Clinic for Diagnostic and Interventional Neuroradiology, University Hospital Technical University Aachen, Pauwelsstraße 30, 52057, Aachen, Germany. .,, Theaterstr. 31, 52062, Aachen, Germany.
| | - T Krings
- UHN Division of Neuroradiology, Toronto Western Hospital, University of Toronto, 399 Barhurst St 3MCL-429, M5T 2S8, Toronto, ON, Canada
| | - J Otto
- Clinic for Diagnostic and Interventional Neuroradiology, University Hospital Technical University Aachen, Pauwelsstraße 30, 52057, Aachen, Germany
| | - M Mull
- Clinic for Diagnostic and Interventional Neuroradiology, University Hospital Technical University Aachen, Pauwelsstraße 30, 52057, Aachen, Germany
| | - J M Schroeder
- Institute of Neuropathology, University Hospital Technical University Aachen, Pauwelsstraße 30, 52057, Aachen, Germany
| |
Collapse
|
30
|
Otto J, Schaudinn A, Linder N, Garnov N, Stolzenburg J, Moche M, Kahn T, Busse H. Prostatakarzinom: Radiologische Intervention. ROFO-FORTSCHR RONTG 2015. [DOI: 10.1055/s-0035-1551446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Doyen J, Bondiau P, Benezery K, Pellegrin A, Poudenx M, Otto J, Leysalle A. PD-0425: Incidence of hippocampal/peri-hippocampal brain metastasis in metastatic small cell lung cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40421-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015; 26:238-244. [PMID: 25344360 DOI: 10.1093/annonc/mdu484] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Patients with advanced lung adenocarcinomas expressing ALK rearrangements are highly responsive to crizotinib, a dual ALK/c-MET inhibitor. Immunohistochemistry (IHC) is an easy clinically and routinely applicable cost-effective assay for ALK, c-MET and ROS1 protein expression for potential treatment with crizotinib. The purpose of this study was to evaluate the percentage and the pattern of ALK-rearranged cells, the variation in the native ALK copy number, as well as ALK, c-MET and ROS1 protein expression, and their significance on outcome of crizotinib-treated lung adenocarcinoma patients. PATIENTS AND METHODS Consecutive lung adenocarcinoma specimens (n = 176) 'double-negative' (wild-type EGFR and KRAS) were tested for ALK rearrangements/copy number alterations and for ALK, c-MET and ROS1 protein expression using automated standardized protocols. Preliminary data on the outcome of crizotinib-treated patients were recorded. RESULTS FISH analysis identified 26/176 (15%) cases with ALK rearrangements. Seven cases had discordant results between the ALK FISH and IHC. Five cases with discordant FISH-positive/IHC-negative revealed FISH 'borderline' positivity (15%-20%). Three cases overexpressed c-MET and responded to crizotinib, and two cases with ALK-'borderline' rearranged cells only, not associated with c-MET expression, progressed under crizotinib. Two cases with discordant FISH-negative/IHC-positive revealed ALK gene amplification without associated c-MET or ROS1 protein expression. CONCLUSIONS The discrepancies observed between the IHC and FISH data revealed unexpected biological events, rather than technical issues, which potentially can have a strong impact on the therapeutic strategy with crizotinib.
Collapse
Affiliation(s)
- M I Ilie
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice; IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice
| | - C Bence
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice; IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice; Hospital Integrated Biobank
| | - E Long-Mira
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice; IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice
| | - C Butori
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice
| | | | - S Lalvée
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice
| | - J Mouroux
- IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice; Department of Thoracic Surgery, Pasteur Hospital, Nice
| | | | - J Otto
- Department of Pneumology, Centre Antoine Lacassagne, Nice, France
| | - C H Marquette
- IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice; Department of Pneumology
| | - P Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice; IRCAN Team 3, INSERM U1081/UMR CNRS 7284, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice; Hospital Integrated Biobank.
| |
Collapse
|
33
|
Moro-Sibilot D, Scherpereel A, Mennecier B, Otto J, Mazières J, Clement-Duchene C, Yurasov S, Zimmermann A, Cuyun Carter G, Garon EB, Pérol M. REVEL : étude randomisée de phase III, en double insu, évaluant l’association docétaxel (D)-ramucirumab (R) versus D plus placebo (P) en deuxième ligne de traitement du CBNPC de stade IV. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Doyen J, Leysalle A, Poudenx M, Otto J, Venissac N, Angellier G, Padovani B, Bondiau P. Chimioradiothérapie concomitante suivie d’une irradiation stéréotaxique des cancers bronchiques non à petites cellules : essai de phase 1 CYBERTAXCIS. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Gawlitza M, Quäschling U, Hobohm C, Otto J, Voigt P, Hoffmann KT, Lobsien D. Hyperintense basilar artery on FLAIR MR imaging: diagnostic accuracy and clinical impact in patients with acute brain stem stroke. AJNR Am J Neuroradiol 2014; 35:1520-6. [PMID: 24812014 DOI: 10.3174/ajnr.a3961] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE FLAIR-hyperintense vessels are known to be a sign of sluggish collateral blood flow in hemispheric vessel occlusion. Additionally, they seem to have a prognostic implication. The aim of the current study was to evaluate the hyperintense configuration of the basilar artery (FLAIR-hyperintense basilar artery) as a marker of basilar artery occlusion and as a predictor of patient outcome. MATERIALS AND METHODS We retrospectively identified 20 patients with basilar artery occlusion who initially underwent MR imaging with subsequent DSA. The diagnostic accuracy of the FLAIR-hyperintense basilar artery sign was tested by 4 independent readers in a case-control design, and the relation among FLAIR-hyperintense basilar artery and DWI posterior circulation-ASPECTS, patient outcome, and patient survival was evaluated. To grade the extent of the FLAIR-hyperintense basilar artery sign, we generated a score by counting the number of sections from the basilar tip to the foramen magnum in which a hyperintense signal in the vessel lumen was present multiplied by the section thickness. RESULTS The FLAIR-hyperintense basilar artery sign showed moderate sensitivity (65%-95%) but very good specificity (95%-100%) and accuracy (85%-93%) for the detection of basilar artery occlusion. Substantial or excellent inter-reader agreement was observed (Cohen κ, 0.64-0.85). The FLAIR-hyperintense basilar artery inversely correlated with the posterior circulation-ASPECTS (r = -0.67, P = .01). Higher FLAIR-hyperintense basilar artery scores were associated with patient death (28.3 ± 13.7 versus 13.4 ± 11.1, P < .05). CONCLUSIONS The FLAIR-hyperintense basilar artery sign proved to be a valuable marker of vessel occlusion and may substantially support the diagnosis of basilar artery occlusion. The established FLAIR-hyperintense basilar artery score may be helpful for the prediction of individual patient survival.
Collapse
Affiliation(s)
- M Gawlitza
- From the Departments of Neuroradiology (M.G., U.Q., K.-T.H., D.L.)Diagnostic and Interventional Radiology (M.G., J.O., P.V.)
| | - U Quäschling
- From the Departments of Neuroradiology (M.G., U.Q., K.-T.H., D.L.)
| | - C Hobohm
- Neurology (C.H.), University Hospital Leipzig, Leipzig, Germany
| | - J Otto
- Diagnostic and Interventional Radiology (M.G., J.O., P.V.)
| | - P Voigt
- Diagnostic and Interventional Radiology (M.G., J.O., P.V.)
| | - K-T Hoffmann
- From the Departments of Neuroradiology (M.G., U.Q., K.-T.H., D.L.)
| | - D Lobsien
- From the Departments of Neuroradiology (M.G., U.Q., K.-T.H., D.L.)
| |
Collapse
|
36
|
Hansen NL, Otto J, Ciritsis A, Barabasch A, Klinge U, Kuhl C, Krämer N. MRT-Evaluation des Therapieerfolgs von Leistenhernien in Patienten mit eisenhaltigen Netzimplantaten. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1372827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
37
|
Otto J, Thörmer G, Do MH, Stolzenburg JU, Garnov N, Reiss-Zimmermann M, Moche M, Kahn T, Busse H. Prospektiver Nutzen einer Endorektalspule bei der 3-T MRT-Bildgebung und Tumordetektion in der Prostata. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1373615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Otto J, Thörmer G, Garnov N, Hoang Do M, Stolzenburg JU, Linder N, Schaudinn A, Kahn T, Moche M, Busse H. Transrektale Prostatabiopsien in einem konventionellen 3-T MRT – erste klinische Erfahrungen mit einer Navigationsoption. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1373464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Otto J, Thörmer G, Seiwerts M, Fuchs J, Garnov N, Franz T, Horn LC, Do M, Stolzenburg JU, Kahn T, Moche M, Busse H. Value of Endorectal Magnetic Resonance Imaging at 3T for the Local Staging of Prostate Cancer. ROFO-FORTSCHR RONTG 2014; 186:795-802. [DOI: 10.1055/s-0033-1356186] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- J. Otto
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - G. Thörmer
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - M. Seiwerts
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - J. Fuchs
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - N. Garnov
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - T. Franz
- Department of Urology, Leipzig University Hospital
| | - L.-C. Horn
- Institute of Pathology, University of Leipzig
| | - M. Do
- Department of Urology, Leipzig University Hospital
| | | | - T. Kahn
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - M. Moche
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| | - H. Busse
- Department of Diagnostic and Interventional Radiology, Leipzig University Hospital
| |
Collapse
|
40
|
|
41
|
Leysalle A, Doyen J, Benezery K, Otto J, Poudenx M, Bondiau PY. Étude rétrospective de 38 patients traités par irradiations en conditions stéréotaxiques par CyberKnife® pour des tumeurs centrales pulmonaires (expérience du centre Antoine-Lacassagne). Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Doyen J, Leysalle A, Poudenx M, Otto J, Angellier G, Padovani B, Venissac N, Bondiau PY. Chimioradiothérapie concomitante suivie d’une irradiation stéréotaxique dans les cancers bronchiques non à petite cellules : essai de phase 1 CYBERTAXCIS. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Hansen NL, Barabasch A, Distelmaier M, Ciritsis A, Kühnert N, Otto J, Conze J, Kuhl CK, Krämer NA. Erstmalige MRT-Visualisierung von chirurgischen eisenhaltigen Netzimplantaten bei Patienten mit Leistenhernie. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
44
|
Otto J, Thörmer G, Schröder C, Garnov N, Moche M, Kahn T, Busse H. Evaluation von diffusionsgewichteter MRT, MR-Spektroskopie sowie deren Kombination zur Vorhersage der Tumoraggressivität beim Prostatakarzinom im Vergleich mit dem postoperativ bestimmten Gleason-Scor. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Otto J, Thörmer G, Garnov N, Moche M, Kahn T, Busse H. Variabilität von absoluten und normierten ADC-Werten beim Prostatakarzinom in Abhängigkeit vom Einsatz einer Endorektalspule sowie der zur Berechnung herangezogenen b-Werte. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Poudenx M, Bondiau PY, Chamorey E, Venissac N, Otto J, Pourel N, Castelnau O, Tessier E, De Surmont Salasc B, Berdah JF, Pop D, Michel C, Mouroux J. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial. Oncology 2012; 83:321-8. [PMID: 22986621 DOI: 10.1159/000342081] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Accepted: 07/23/2012] [Indexed: 02/03/2023]
Abstract
Concurrent chemoradiotherapy (CHRT) is the standard of care for unresectable locally advanced stage III non-small cell lung cancer. However, the optimal combination remains unclear. The aim of this study was to evaluate the efficacy of 2 induction chemotherapy cycles (days 1 and 22) with docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) followed by concurrent chemotherapy (weekly docetaxel-cisplatin, 20 mg/m(2)) and 3-D conformal radiotherapy for 6 weeks (66 Gy/5 fractions per week/2 Gy per fraction). The primary endpoint was the response rate. Secondary objectives were toxicity, time to progression, and overall survival. Forty-four patients were included and 40 were eligible. The mean age was 60.5 years (range 40.7-72.1), and 75% had stage IIIB disease. Six patients underwent complete R0 resection including 2 pathologic complete responses after a planned intermediate evaluation. Thirty-three patients completed CHRT. The objective response rate was 65% (95% CI 50.2-79.8). Grade 3-4 hematologic and digestive toxicities were observed mainly during the induction phase. Grade 3 esophagitis (5%) was experienced during CHRT. With a median follow-up of 38.7 months, the median progression-free survival was 28.3 months (95% CI 11.0-35.0) and the median survival rate was 31.4 months. Cisplatin-docetaxel induction followed by concurrent 3-D conformal radiotherapy and weekly chemotherapy is a feasible protocol associated with a promising response rate and acceptable toxicity.
Collapse
Affiliation(s)
- M Poudenx
- Centre Antoine Lacassagne, Nice, France. michel.poudenx @ nice.unicancer.fr
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Doyen J, Poudenx M, Eriksson P, Otto J, Venissac N, Angellier G, Hérault J, Bondiau PY. Étude de phase I sur l’ajout d’une radiothérapie ablative dans le cancer bronchique non à petites cellules de stade III : résultats préliminaires. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Hennis PJ, Meale PM, Hurst RA, O'Doherty AF, Otto J, Kuper M, Harper N, Sufi PA, Heath D, Montgomery HE, Grocott MPW. Cardiopulmonary exercise testing predicts postoperative outcome in patients undergoing gastric bypass surgery. Br J Anaesth 2012; 109:566-71. [PMID: 22810563 DOI: 10.1093/bja/aes225] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND For several types of non-cardiac surgery, the cardiopulmonary exercise testing (CPET)-derived variables anaerobic threshold (AT), peak oxygen consumption (VO2 peak), and ventilatory equivalent for CO(2) (VE/VCO2 ) are predictive of increased postoperative risk: less physically fit patients having a greater risk of adverse outcome. We investigated this relationship in patients undergoing gastric bypass surgery. METHODS All patients (<190 kg) who were referred for CPET and underwent elective gastric bypass surgery at the Whittington Hospital NHS Trust between September 1, 2009, and February 25, 2011, were included in the study (n=121). Fifteen patients did not complete CPET. CPET variables (VO2 peak, AT, and VE/VCO2 ) were derived for 106 patients. The primary outcome variables were day 5 morbidity and hospital length of stay (LOS). The independent t-test and Fisher's exact test were used to test for differences between surgical outcome groups. The predictive capacity of CPET markers was determined using receiver operating characteristic (ROC) curves. RESULTS The AT was lower in patients with postoperative complications than in those without [9.9 (1.5) vs 11.1 (1.7) ml kg(-1) min(-1), P=0.049] and in patients with a LOS>3 days compared with LOS ≤ 3 days [10.4 (1.4) vs 11.3 (1.8) ml kg(-1) min(-1), P=0.023]. ROC curve analysis identified AT as a significant predictor of LOS>3 days (AUC 0.640, P=0.030). The VO2 peak and VE/VCO2 were not associated with postoperative outcome. CONCLUSIONS AT, determined using CPET, predicts LOS after gastric bypass surgery.
Collapse
Affiliation(s)
- P J Hennis
- Portex Unit, UCL Institute of Child Health, London, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Schulze H, Bischoff A, Palme H, Spettel B, Dreibus G, Otto J. Mineralogy and chemistry of Rumuruti: The first meteorite fall of the new R chondrite group. ACTA ACUST UNITED AC 2012. [DOI: 10.1111/j.1945-5100.1994.tb00681.x] [Citation(s) in RCA: 113] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
50
|
Thörmer G, Otto J, Schröder C, Garnov N, Reiss-Zimmermann M, Horn LC, Do M, Stolzenburg JU, Moche M, Kahn T, Busse H. Wertigkeit der diffusionsgewichteten und spektroskopischen MR-Bildgebung für eine Vorhersage der Tumoraggressivität beim Prostatakarzinom. ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|